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The inclusion compounds isolated from nonaqueous solutions of heptakis(2,6-di-O-methyl)--
cyclodextrin (DIMEB) and the complexes [CpMoL2(CO)2](BF4) (L ) MeCN, L2 ) 2,2′-biimidazole)
were characterized in the solid state by powder X-ray diffraction (XRD), thermogravimetric analysis
(TGA), 13C{1H} CP/MAS NMR, and FTIR spectroscopy. Powder XRD showed that the compound with
[CpMo(MeCN)2(CO)2](BF4) was amorphous, while that with [CpMo(H2biim)(CO)2](BF4) was microc-
rystalline. The powder XRD pattern of the microcrystalline product could be satisfactorily indexed in
the orthorhombic crystal system with space group P212121 and final unit cell parameters of a ) 28.489(3)
Å, b ) 19.198(2) Å, and c ) 16.042(2) Å. A hypothetical structural model for the crystal packing was
obtained through Monte Carlo optimizations using fixed DIMEB, [CpMo(H2biim)(CO)2]+, and BF4-
geometries. In the final model the BF4- anions are housed inside the toroidal cavity of DIMEB and the
organometallic complex cations are regularly distributed in between the DIMEB-tetrafluoroborate
complexes, occupying the intermolecular void spaces. The cytotoxicity of the free complexes and the
corresponding DIMEB adducts was tested against K1735-M2 mouse melanoma cells and H9c2 rat myoblast
cells in aqueous solution. The MeCN complex and its corresponding DIMEB adduct showed no significant
activity for use as chemotherapeutic agents. In contrast, the biimidazole complex exhibited significant
cytotoxicity against K1735-M2 cells, especially for concentrations above 50 µM, and the cytotoxicity
was even higher when the DIMEB adduct was used. Epifluorescence microscopy indicated that
mitochondrial alterations took place at an earlier time point than major changes in cell morphology.
Introduction
Toward the end of the 1970s, inorganic compounds started
to have a tremendous impact on medicine, mainly due to
Rosenberg’s serendipitous discovery of the potent antitumor
activity of cisplatin, a square-planar PtII complex (cis-dichlo-
rodiamineplatinum(II)).1 Cisplatin continues to be used in
50-70% of all cancer patients, with particular activity against
testicular, ovarian, bladder, and neck cancers. The drug does,
however, present severe side effects such as nephrotoxicity,
neurotoxicity, and emesis, and many human cancers either have
a natural resistance to cisplatin or acquire resistance during
treatment. In an effort to overcome these problems, modified
versions of cisplatin have been studied, such as the second-
generation drug carboplatin, which exhibits reduced toxicity,
and the third generation drug satraplatin, the first orally
bioavailable platinum drug.2 There has also been a huge effort
to develop other metal coordination complexes as antitumor
agents.3 Two ruthenium-based complexes, namely, (ImH)[trans-
RuCl4(DMSO-κS)(Im)] (Im ) imidazole, DMSO-κS ) S-
bonded dimethylsulfoxide) (NAMI-A) and (IndH)[trans-
RuCl4(Ind)2] (Ind ) indazole) (KP1019), have successfully
completed phase 1 clinical trials and are scheduled to enter phase
2 trials in the near future.4,5
One of the potential drawbacks of using coordination
complexes as antitumor agents is their instability and compli-
cated ligand exchange chemistry. Although some exchange
reactions are essential for inducing the appropriate therapeutic
properties, others can lead to drug deactivation and detoxifica-
tion. Accordingly, it has been suggested that organometallic
compounds might be better drug candidates because they exhibit
slow rates of ligand dissociation in biological systems.6 The
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field of organometallic pharmaceuticals is not a new one and
dates back to the pioneering work of Ko¨pf and Ko¨pf-Maier,
who investigated the antitumor activity of bent metallocene
complexes of the type Cp2MX2 (M ) Ti, V, Nb, Mo; e.g., X )
Cl, Br, acido ligand).7 Titanocene dichloride was the first
nonplatinum metal complex to enter clinical trials. However,
the hydrolytic instability and disappointing phase 2 results of
Cp2TiCl2 have prompted investigators to focus on derivatives
of Cp2TiCl2 and related metallocenes.8,9 The search for effective
organometallic drug candidates has extended to a broad variety
of compounds, including, for example, the vectorization of
cyclopentadienyl compounds with tamoxifen,10 and ruthe-
nium(II) arene complexes.5,6
The eventual clinical application of metal-based drugs may
depend to a large extent on developing methods to safely
shepherd the drugs through specific areas of the body. Molecular
encapsulation is one approach that has the potential to overcome
a number of hurdles, for example poor aqueous solubility and
stability and high toxicity. Organic host molecules such as
cyclodextrins (CDs) and cucurbiturils have been identified as
potentially useful carrier and protecting agents for anticancer
complexes,11,12 with considerable attention being focused on
CDs due to their frequent use in drug delivery formulations.13
CDs are water-soluble cyclic oligosaccharides capable of
forming inclusion complexes with a wide range of organic
molecules, inorganic ions, and metallo-organic species.14 Inclu-
sion complexes containing CDs and the anticancer agents
carboplatin11a-c and Cp2MX2 (M ) Ti, V, Nb, Mo)11e-i have
already been described. Utsuki et al. reported that interstitial
delivery of a carboplatin-HPRCD complex from a microencap-
sulated formulation was effective against an experimental rat
glioma model.15 Cytotoxicity experiments carried out on human
adenocarcinoma cells indicated that the antitumor activity of
Cp2MoCl2 can be enhanced by association with cyclodextrins.16
We recently described structural studies of inclusion com-
plexes comprising [CpMoL2(CO)2](BF4) (L ) MeCN, L2 )
2,2′-biimidazole; Chart 1) encapsulated in -CD and hep-
takis(2,3,6-tri-O-methyl)--CD (TRIMEB) hosts.17 Half-sand-
wich complexes of molybdenum are worth considering as
potential metallopharmaceuticals because they exist in a wide
range of oxidation states and are compatible with a large array
of ligands.18 In the present work, we have extended the study
to include the modified CD heptakis(2,6-di-O-methyl)--CD
(DIMEB) as host molecule. The superior solubilizing properties
of DIMEB make it an attractive delivery agent for drug
molecules.13,19 The inclusion complexes have been characterized
in the solid state by various techniques and screened for their
cytotoxicity against two different nonhuman cell lines.
Results and Discussion
Preparation of the Inclusion Complexes. A solution of
DIMEB in acetonitrile or dichloromethane was added to
solutions of [CpMo(MeCN)2(CO)2](BF4) (1) in acetonitrile or
[CpMo(H2biim)(CO)2](BF4) (2) in dichloromethane, and the
resultant mixtures were heated at 40 °C for 2 h. A host:guest
molar ratio of 1:1 was used for both systems. After evaporation
of the solvents under reduced pressure, the products referred to
as 1@DIMEB and 2@DIMEB were obtained as light red and
light brown solids, respectively.
Powder Diffraction and ab Initio Structural Modeling.
When a crystalline phase is obtained, powder X-ray diffraction
allows the identification of true inclusion complexes of cyclo-
dextrins, mainly based on the empirical evidence that the powder
XRD patterns of these compounds should be clearly distinct
from those obtained by the superimposition of the diffractograms
for each individual component.20 However, we were able to
isolate the adduct 2@DIMEB only as a crystalline phase; the
adduct 1@DIMEB, in spite of several efforts at recrystallization,
always formed an amorphous phase. Still, this is a good early
indication of the stability of 1@DIMEB, as there was no
separation of its components in any of these experiments.
Structural investigations of the crystal packing fashion of
2@DIMEB from powder X-ray data were performed using the
systematic experimental considerations previously described for
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D. R.; Ashton, P. R.; Lilley, T. H.; Stoddart, J. F.; Zarzycki, R.; Slawin,
A. M. Z.; Williams, D. J. Carbohydr. Res. 1989, 192, 259. (d) Horvath,
G.; Premkumar, T.; Boztas, A.; Lee, E.; Jon, S.; Geckeler, K. E. Mol. Pharm.
2008, 5, 358. (e) Turel, I.; Demsˇar, A.; Kosˇmrlj, J. J. Inclusion Phenom.
Macrocyclic Chem. 1999, 35, 595. (f) Vinkla´rek, J.; Honzı´cˇek, J.; Holubova´,
J. Central Eur. J. Chem 2005, 3, 72. (g) Pereira, C. C. L.; Nolasco, M.;
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E. J. Inclusion Phenom. Macrocyclic Chem. 2008, 60, 263. (i) Braga, S. S.;
Gonc¸alves, I. S.; Pillinger, M.; Ribeiro-Claro, P.; Teixeira-Dias, J. J. C. J.
Organomet. Chem. 2001, 632, 11.
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Trans. 2006, 451. (b) Buck, D. P.; Abeysinghe, P. M.; Cullinane, C.; Day,
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20, 341. (b) Davis, M. E.; Brewster, M. E. Nat. ReV. Drug DiscoVery 2004,
3, 1023. (c) Challa, R.; Ahuja, A.; Ali, J.; Khar, R. K. AAPS PharmSciTech
2005, 6, E329. (d) Uekama, K.; Hirayama, F.; Arima, H. J. Inclusion
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other inclusion complexes of cyclodextrins,11g,21 in particular
for Cp2NbCl2@TRIMEB11g and CpMo(CO)3Cl@TRIMEB.21a
Crystalline CD inclusion complexes can generally be grouped
into distinct isostructural series according to the type of crystal
packing arrangement.22 Within an isostructural series, the gross
features of the powder XRD patterns are constant, regardless
of the nature of the included guest. To the best of our
knowledge, there are no reports in the literature of true
host-guest systems in which DIMEB molecules encapsulate
organometallic complexes. Indeed, a search of the Cambridge
Structural Database23 (CSD, Version 5.28, three updates,
November 2007) revealed only structures with organic guest
molecules.24 A preliminary comparison of the powder XRD
pattern of 2@DIMEB with those of complexes with DIMEB
and organic guests indicated the presence of a host-guest
system. Of all the DIMEB structures reported to date,24 only
two crystallize in the monoclinic P21 space group (CSD refcodes
QAZYIZ and SAJPOI).24d Thus, following the isostructurality
concepts developed by Caira,22 2@DIMEB would most likely
crystallize in the orthorhombic crystal system with space group
P212121.
The experimental powder XRD pattern of 2@DIMEB exhibits
several features typical of powdered cyclodextrin inclusion
compounds, in particular a significant reduction in overall
crystallinity compared with pure DIMEB (driven by the inherent
structural disorder associated with the host-guest system and
the water molecules of crystallization, affected by thermal
disorder and housed in the empty voids), poorly resolved
reflections at low angle, a significant background up to ca. 30°
2θ, and the absence of discernible reflections from the back-
ground at higher angles. Nevertheless, by selecting the first 15
more intense and well-resolved reflections, located using the
derivative-based peak search algorithm in Fullprof.2k,25 the
powder pattern could be indexed using DICVOL04,26 for which
a fixed absolute error on each line of 0.03° 2θ was employed
and no impurity lines were allowed. Initial unit cell metrics in
the orthorhombic crystal system were calculated with reasonable
figures-of-merit: M(15)27a ) 14.8 and F(15)27b ) 41.5. Sys-
tematic absences were examined using the software package
CHECKCELL,28 which unambiguously confirmed the space
group P212121 as the most suitable to describe the overall
symmetry of the compound. A Le Bail29 whole-powder-
diffraction-pattern profile decomposition using fixed (and manu-
ally selected) background points produced a reasonable fitting
(RBragg ) 0.36% and 2 ) 10.7; see Figure S1 in the Supporting
Information) with the unit cell parameters converging to a )
28.489(3) Å, b ) 19.198(2) Å, and c ) 16.042(2) Å.
The crystal structure modeling and the final selection of a
chemically feasible hypothetical packing for 2@DIMEB using
the software package FOX30 assumed a priori that (1) due to
electrostatic interactions, the [CpMo(H2biim)(CO)2]+ cation and
the charge-balancing BF4– anion should be in close proximity;
(2) individual chemical moieties are distributed in order to
effectively fill the available space; (3) interactions between guest
molecules and the host DIMEB are essentially of relatively weak
nature, being a combination of hydrogen bonds and van der
Waals interactions; (4) the overall diffraction of the material is
mainly due to the large chemical moieties, and the omission of
individual water molecules from the initial model for Monte
Carlo optimization will not have a significant impact on the
final result; and (5) the molecular geometry of each chemical
moiety remains relatively unchanged after inclusion. This latter
assumption is critical because a crystal structure of a DIMEB
inclusion compound with an organometallic complex is not
available in the literature. Consequently, it is necessary to select
a conformation for DIMEB from one of the known compounds
and assume that it will not be very different from that adopted
in a true inclusion compound with an organometallic guest.
The molecular geometrical parameters of the [CpMo-
(H2biim)(CO)2]+ cation and the BF4- anion were extracted from
the reported crystal structure,17 with the central molybdenum
and boron atoms being taken as the pivot atoms of the
corresponding Fenske-Hall Z-matrices created using BABEL
(hydrogen atoms were removed to simplify the calculations).31
This strategy facilitates the mobility of these chemical entities
(treated as rigid bodies) inside the unit cell boundaries during
the global optimization processes. For DIMEB, several different
conformations reported in the literature, each exhibiting distinct
elliptical distortions of the toroidal cavity, were used, all of them
invariably leading to approximately the same final result. For
the structural model described here, we selected the DIMEB
geometry of the compound reported by Selkti et al. (CSD
refcode NITSIS)32 since it minimizes the number of overlapping
neighboring atoms between adjacent moieties.
Monte Carlo optimizations using the optimized parallel
tempering algorithm were launched in FOX30 with the three
individual mathematical objects having the parameters of the
Z-matrices fixed (i.e., each entity was treated as a rigid body).
Since the experimental data were collected in an instrument with
a Bragg-Brentano geometry and the crystal habit of cyclodex-
trin compounds is usually plate-like, the powder XRD pattern
was assumed a priori to be affected by textural effects such as
preferred orientation, and a refineable March-Dollase correc-
tion33 was included in the optimization. Antibump restraints and
water molecules of crystallization were omitted from the
(21) (a) Braga, S. S.; Paz, F. A. A.; Pillinger, M.; Seixas, J. D.; Roma˜o,
C. C.; Gonçalves, I. S. Eur. J. Inorg. Chem. 2006, 1662. (b) Fernandes,
J. A.; Lima, S.; Braga, S. S.; Ribeiro-Claro, P.; Rodriguez-Borges, J. E.;
Teixeira, C.; Pillinger, M.; Teixeira-Dias, J. J. C.; Goncalves, I. S. J.
Organomet. Chem. 2005, 690, 4801. (c) Petrovski, Z.; Braga, S. S.; Santos,
A. M.; Rodrigues, S. S.; Gonc¸alves, I. S.; Pillinger, M.; Kühn, F. E.; Roma˜o,
C. C. Inorg. Chim. Acta 2005, 358, 981.
(22) Caira, M. R. ReV. Roumaine Chim. 2001, 46, 371.
(23) (a) Allen, F. H. Acta Crystallogr., Sect. B: Struct. Sci. 2002, 58,
380. (b) Allen, F. H.; Motherwell, W. D. S. Acta Crystallogr., Sect. B:
Struct. Sci. 2002, 58, 407.
(24) DIMEB inclusion compounds have the CSD refcodes BOYGAX,
COFLOY, DEZMIE10, DEZMOK10, NITSIS, PABNEM, QAZYEV,
QAZYIZ, SAJPOI, WAGHAN01, and YAPSEN10 and can be found in
the following references:(a) Tsorteki, F.; Mentzafos, D. Carbohydr. Res.
2002, 337, 1229. (b) Harata, K. Chem. Commun. 1999, 191. (c) Armspach,
D.; Ashton, P. R.; Ballardini, R.; Balzani, V.; Godi, A.; Moore, C. P.; Prodi,
L.; Spencer, N.; Stoddart, J. F.; Tolley, M. S.; Wear, T. J.; Williams, D. J.
Chem.-Eur. J. 1995, 1, 33. (d) Harata, K.; Hirayama, F.; Uekama, K.;
Tsoucaris, G. Chem. Lett. 1988, 1585. (e) Harata, K. Bull. Chem. Soc. Jpn.
1988, 61, 1939. (f) Pohlmann, H.; Gdaniec, M.; Eckle, E.; Geiger, G.;
Stezowski, J. J. Acta Crystallogr., Sect. A: Found. Crystallogr. 1984, 40,
C276.
(25) (a) Rodriguez-Carvajal, J. FULLPROF-A Program for Rietveld
Refinement and Pattern Matching Analysis. Abstract of the Satellite Meeting
on Powder Diffraction of the XV Congress of the IUCR; Toulouse, France,
1990; p 127. (b) Roisnel, T., Rodriguez-Carvajal, J. WinPLOTR [June
2005]-A Windows Tool for Powder Diffraction Pattern Analysis. Proceed-
ings of the SeVenth European Powder Diffraction Conference (EPDIC 7),
Mater. Sci. Forum; 2001; Vols. 378-381, pp 118-123.
(26) Boultif, A.; Louer, D. J. Appl. Crystallogr. 2004, 37, 724.
(27) (a) Boultif, A.; Louer, D. J. Appl. Crystallogr. 1991, 24, 987. (b)
Louer, D. In Automatic Indexing: Procedures and Applications, Accuracy
in Powder Diffraction II; Gaithersburg, MD, 1992; pp 92-104.
(28) Laugier, J., Bochu, B. CHECKCELL-A Software Performing
Automatic Cell/Space Group Determination; Collaborative Computational
Project Number 14 (CCP14); Laboratoire des Mate´riaux et du Ge´nie
Physique de l’Ecole Supe´rieure de Physique de Grenoble (INPG): France,
2000.
(29) LeBail, A.; Duroy, H.; Fourquet, J. L. Mater. Res. Bull. 1988, 23,
447.
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structural model. Several optimizations were launched at the
same time, all starting from distinct random crystallographic
positions for the three chemical moieties. All models converged
to nearly the same spatial distribution of the host and guest
molecules with comparable R factors.
After full convergence of the Monte Carlo optimization
(approximately three full days of computation), the permutation
in P212121 of the three chemical entities produced a structural
model whose simulated powder pattern compares well with the
experimental one, with a calculated weighted residual of Rwp
) 0.102 (Figure 1). Fractional atomic coordinates and a CIF
file for the hypothetical structural model are supplied as
Supporting Information. Remarkably, these structural studies
clearly demonstrate that in 2@DIMEB the chemical moiety
housed inside the toroidal cavity of DIMEB is the BF4- anion
instead of the expected cationic organometallic complex (Figure
2). However, the two charged species are still in close proximity,
with a Mo · · · B distance of ca. 5.96 Å, which is slightly longer
than the analogous value of ca. 5.05 Å found in the crystal
structure of [CpMo(H2biim)(CO)2](BF4) (2),17 most likely due
to the presence of the bulky DIMEB molecule. In the structural
model of 2@DIMEB, the cations are regularly distributed in
between the DIMEB hosts, occupying the intermolecular void
spaces (Figures 3 and 4). This unusual structural feature is not
unprecedented and was previously reported by K. Harata for
the DIMEB complexes with p-iodophenol and p-nitrophenol.24e
Thermal Behavior. Figure 5 compares the TGA curves of
1@DIMEB and 2@DIMEB with those of DIMEB and 1:1
physical mixtures of DIMEB and either complex 1 or 2. DIMEB
decomposes abruptly in the temperature range 325-410 °C with
a mass loss of 87%, followed by a smoother loss of 8% up to
600 °C. In the physical mixture of DIMEB and complex 1,
prepared by grinding the two components together at room
temperature, the well-defined step centered around 150 °C (ca.
5% mass loss) corresponds to the removal of the acetonitrile
and CO ligands from the complex,17 and DIMEB decomposition
is shifted by about 40 °C to lower temperature compared with
the pure CD. The lower thermal stability of the cyclodextrin in
the physical mixture is probably induced by the second-stage
decomposition of the organometallic complex, which extends
from about 250 to 500 °C and involves the decomposition of
the cyclopentadienyl group and the tetrafluoroborate counte-
rion.17 Compound 1@DIMEB exhibits a somewhat different
TG behavior. After removal of water molecules from room
temperature to ca. 80 °C (3.7% mass loss), the initial fragmenta-
tion of the complex appears as a broad step centered around
150 °C, and the organic macrocycle begins to decompose at
about 240 °C, compared with 300 °C for the physical mixture
(and 340 °C for pure DIMEB). The temperature of 240 °C
roughly corresponds to the point where the second-stage
decomposition of complex 1 begins, indicating that the three
components, DIMEB, [CpMo(MeCN)2(CO)2]+, and BF4-, are
in intimate contact in 1@DIMEB. Comparable results were
obtained with 2@DIMEB (Figure 5), the main difference being
that no obvious step is present for the decomposition of the
organometallic complex because the pure complex 2 decom-
poses in a series of overlapping steps that extend from room
temperature to 475 °C.17
Spectroscopic Characterization. The 13C{1H} CP/MAS
NMR spectra of DIMEB, 1@DIMEB, and 2@DIMEB are
shown in Figure 6. The spectrum for DIMEB is in agreement
with that reported by Takashimi et al.34 and can be assigned on
the basis of the well-known spectra for unmodified -CD and
permethylated -CD (TRIMEB).11g In the spectra of 1@DIMEB
and 2@DIMEB, the signals for the cyclodextrin carbon atoms
are slightly broader than those of pure DIMEB, which could
be due to differences in crystallinity (especially for 1@DIMEB)
and/or a change in the structure of DIMEB to a more
(30) (a) Favre-Nicolin, V.; Cerny´, R. J. Appl. Crystallogr. 2002, 35,
734. (b) Favre-Nicolin, V., Cerny´, R. FOX-A Program for ab Initio
Structure Solution from Powder Diffraction Data; Program Developed for
the Swiss National Science Foundation; University of Geneva: Geneva,
Switzerland, 2000.
(31) Walters, P.; Stahl, M. BABEL Version 1.3-A Program for the
InterconVersion of File Formats Used in Molecular Modelling; Department
of Chemistry, University of Arizona: Tucson, AZ, 1996.
(32) Selkti, M.; Navaza, A.; Villain, F.; Charpin, P.; De Rango, C.
J. Inclusion Phenom. Macrocyclic Chem. 1997, 27, 1.
(33) (a) March, A. Z. Kristallogr. 1932, 81, 285. (b) Dollase, W. A.
J. Appl. Crystallogr. 1986, 19, 267.
(34) Takashimi, Y.; Sakamoto, K.; Oizumi, Y.; Yamaguchi, H.; Kami-
tori, S.; Harada, A. J. Inclusion Phenom. Macrocyclic Chem. 2006, 56, 45.
Figure 1. Experimental (red circles) and FOX-simulated (solid black
line) powder XRD patterns of 2@DIMEB.
Figure 2. Schematic representation of the individual chemical
moieties that make up the asymmetric unit of the hypothetical
structural model of 2@DIMEB. The pendant groups attached to
the seven R-D-glucopyranoside units of DIMEB are drawn in stick
mode and represent (especially -CH2OCH3 and -OCH3) the
moieties that were susceptible to rotation (to avoid structural
overlap) during unrestrained refinement using FOX.
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symmetrical one as a result of complexation with a guest
species.11g,17,21a,34 The 13C{1H} CP/MAS NMR spectrum of
2@DIMEB shows additional signals at 96.9 (Cp), 122.5 and
134.7 (H2biim) for the molybdenum-coordinated ligands, which
are essentially unshifted compared with the corresponding
signals for the free complex 2.17 No Cp resonance could be
observed for 1@DIMEB due to overlap with the broad C1 signal
of DIMEB. For both inclusion compounds it was not possible
to clearly identify the resonances (masked in the background)
of the molybdenum-coordinated CO groups, even when contact
times of 2 ms were used. The presence of these groups was
confirmed by IR spectroscopy. Thus, in addition to the intense
and typical bands of the cyclodextrin host, the spectra contained
two bands in the CO stretching region (1890-1990 cm-1), as
expected for a complex of the type [CpMoL2(CO)2]+. The high-
frequency band for both compounds was unshifted compared
with the corresponding band for the free complex, while the
second band at lower frequency was blue-shifted by about 12
cm-1. The presence of tetrafluoroborate anions in 1@DIMEB
and 2@DIMEB was confirmed by the strong νBF absorption
band at 1087 cm-1.
Cytotoxicity Studies. Two different nonhuman cell lines were
used to investigate the cytotoxicity of the four compounds under
study. K1735-M2 cells are a highly invasive melanoma mouse
Figure 3. Schematic representation of the distribution of DIMEB molecules (represented as large seven-faced polyhedrons) and
[CpMo(H2biim)(CO)2]+ cations (drawn in ball-and-stick mode) along the [001] direction of the unit cell in 2@DIMEB, emphasizing how
the organometallic complexes are located in the intermolecular spaces rather than within the host cavities. BF4- anions are omitted for
clarity.
Figure 4. Crystal packing of 2@DIMEB viewed in perspective
along the [010] (a) and [001] (b) directions of the unit cell. See the
caption to Figure 3 for further details.
Figure 5. Thermogravimetric analysis profiles of DIMEB (s), the
1:1 physical mixture of DIMEB and [CpMo(MeCN)2(CO)2](BF4)
(1) (- · · - · · ), 1@DIMEB (- · - · ), the 1:1 physical mixture
of DIMEB and [CpMo(H2biim)(CO)2](BF4) (2) ( · · · ), and 2@-
DIMEB (- - -).
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cell line,35 which was previously used to investigate the
chemotherapeutic potential of several molecules, including the
alkaloid berberine.36,37 H9c2 is a nontumor rat myoblast cell
line and has been extensively used to investigate the muscle
toxicity of novel and clinically used chemotherapeutics.38,39
Regarding the melanoma cell line, complex 2 has a higher
effect than complex 1, particularly at the highest concentration
of 100 µM (Figure 7, left-hand column). Like complex 1, the
adduct 1@DIMEB had no cytotoxic effect at all, showing that
DIMEB per se does not cause cytotoxic inhibition of cell
proliferation. On the other hand, the adduct 2@DIMEB was
superior to complex 2 in terms of inhibition of K1735-M2 cell
proliferation, especially again at the highest concentration used.
At this concentration, the cytotoxicity of 2@DIMEB was
apparent at an early time point, with a clear inhibitory effect
after 24 h, while the free complex 2 exhibits a noticeable
inhibition (compared to the control group) only after 48 h.
When investigating the behavior of the compounds toward
the H9c2 myoblastic line (Figure 7, right-hand column), the
higher effect of complex 2 when compared with 1 was again
noticeable, and interestingly some concentrations of 1 (especially
10 µM) actually increased cell proliferation. An increase in cell
proliferation was also observed for some concentrations of
1@DIMEB, in particular 1 µM (72 h) and 25 µM (96 h). The
same compound exhibited cytotoxicity when used at the highest
concentration (100 µM), causing inhibition of cell proliferation
for 48 and 96 h. Regarding the inclusion compound 2@DIMEB,
some inhibition of myoblast proliferation was observed, although
the relative effect (when using 100 µM) was lower compared
with the results for the K1735-M2 cells.
In order to obtain preliminary data on the possible mechanism
of cytotoxicity of 2@DIMEB toward the melanoma cell line,
we performed epifluorescence microscopy and investigated
whether early nuclear or mitochondrial alterations due to drug
treatment could be detected (Figure 8). Three different fluo-
rescent probes were used. TMRM is a cationic probe that has
a red fluorescence once accumulated by functional mitochondria.
When the organelle is damaged by a foreign compound and
loses its transmembrane electric potential (negative inside), the
red fluorescence decays. Hoechst 33342 is a probe that binds
to DNA. Condensed chromatin due to apoptotic cell death can
be visualized due to nuclear shrinkage and increased fluores-
cence of the probe. Finally, calcein-AM is a probe for cell
viability. When cells are viable, and hence with intact plasma
membranes, the probe is accumulated inside cells and possesses
green fluorescence. When the membrane is disrupted due to
necrotic cell death, the green fluorescence is lost.
Time points of 24 and 72 h were analyzed. Regarding the
early time point and at the lower concentrations (25 µM), no
alterations were observed in the mitochondrial network or in
nuclear organization. Differences were visible at a concentration
of 50 µΜ, where mitochondrial fragmentation was observed.
The alteration preceded the loss of TMRM fluorescence at the
highest concentration, indicative of complete mitochondrial
depolarization. Nevertheless, despite mitochondrial depolariza-
tion, cells remained viable, as noticed by the retention of
cytosolic calcein (green fluorescence). In accordance with the
cytotoxicity studies, a marked decrease in the number of cells
was observed at the higher concentrations tested. After 72 h,
the most noticeable effect was a decrease in the number of cells
and widespread necrotic phenotype (loss of TMRM and calcein
fluorescence) at the highest concentration as well as mitochon-
drial fragmentation and depolarization in cells with intact plasma
membranes.
Conclusions
This study was motivated by the potential application of half-
sandwich complexes of molybdenum as anticancer agents. The
complexes with the general formula [CpMoL2(CO)2](A) are an
interesting starting point because they represent a relatively large
family of molybdenum(II) derivatives and are compatible with
a broad spectrum of ancillary ligands. In testing the complexes
[CpMo(MeCN)2(CO)2](BF4) (1) and [CpMo(H2biim)(CO)2]-
(BF4) (2) against two different cell lines, each one being an
established model for cytotoxicity analyses, dissimilar results
were obtained. Complex 1 and the adduct 1@DIMEB showed
no significant activity for use as chemotherapeutic agents.
Regarding the myoblastic H9c2 cell lines, cell proliferation
actually increased for some concentrations. The biimidazole
derivative 2 exhibited significant cytotoxicity against the K1735-
M2 cell line, especially at the highest concentrations used.
However, no selectivity was observed since 2 was also toxic
for the myoblast cell line. Even higher cytotoxicity against
K1735-M2 cells was observed when the adduct 2@DIMEB was
(35) Repesh, L. A. InVasion Metastasis 1989, 9, 192.
(36) Pereira, G. C.; Branco, A. F.; Matos, J. A.; Pereira, S. L.; Parke,
D.; Perkins, E. L.; Serafim, T. L.; Sarda˜o, V. A.; Santos, M. S.; Moreno,
A. J.; Holy, J.; Oliveira, P. J. J. Pharmacol. Exp. Ther. 2007, 323, 636.
(37) Serafim, T. L.; Oliveira, P. J.; Sarda˜o, V. A.; Perkins, E.; Parke,
D.; Holy, J. Cancer Chemother. Pharmacol. 2008, 61, 1007.
(38) Turakhia, S.; Venkatakrishnan, C. D.; Dunsmore, K.; Wong, H.;
Kuppusamy, P.; Zweier, J. L.; Ilangovan, G. Am. J. Physiol. Heart Circ.
Physiol. 2007, 293, H3111.
(39) Reeve, J. L.; Szegezdi, E.; Logue, S. E.; Chonghaile, T. N.; O’Brien,
T.; Ritter, T.; Samali, A. J. Cell. Mol. Med. 2007, 11, 509.
Figure 6. 13C{1H} CP/MAS NMR spectra of DIMEB (a),
1@DIMEB (b), and 2@DIMEB (c). Spinning side bands are
denoted by asterisks.
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used. Epifluorescence microscopy of K1735-M2 cells, in turn,
showed that mitochondrial fragmentation and depolarization
occurred at the highest concentrations (50 and 100 µM) of
2@DIMEB, although viability was still maintained, indicating
that ultracellular alterations may be present even before complete
cell death and cell detachment. Despite the fact that the
corresponding mechanism is still unknown, these results appear
to indicate that mitochondrial alterations take place at an earlier
time point than major changes in cell morphology.
The higher cytotoxicity of 2@DIMEB compared with the free
complex was somewhat unexpected, taking into account the
structural model derived from the powder XRD data, which
shows that the species encapsulated in the host cavity is the
tetrafluoroborate anion rather than the half-sandwich MoII
complex cation. This result goes against our previous structural
studies of TRIMEB inclusion complexes with the species
CpMo(CO)3Cl, CpFe(CO)2Cl, and Cp2NbCl2, which revealed
either partial (involving inclusion of the Cp ligands inside the
host cavity) or complete molecular encapsulation.11g,21a,40
Molecular modeling studies of 2@DIMEB, including, for
example, computation of the molecular lipophilicity patterns,41
may help to understand the driving forces responsible for the
formation of this unusual structure. From the perspective of the
organometallic complex cation, 2@DIMEB is more correctly
Figure 7. Inhibition of cell proliferation by complexes 1, 2, 1@DIMEB, and 2@DIMEB as measured by the sulforhodamine B dye assay.
K1735-M2 and H9c2 cells were seeded as described in the Experimental Section and treated with the different compounds for 24-96 h.
Cells in 48-well plates were fixed with 1% acetic acid in methanol. Results are shown as the percentage of time zero, which is an indication
of the increase of cell mass, and hence of cell proliferation. Values are means ( SEM of four different experiments. *p < 0.05 vs control
for the respective time point.
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described as a noninclusion complex. The situation may be
reversed upon dissolution of 2@DIMEB; that is, molecular
encapsulation of [CpMo(H2biim)(CO)2]+ may compete with
encapsulation of BF4-. Even if no inclusion occurs between
the cation and DIMEB, we cannot exclude the presence of a
noninclusion interaction between the two components able to
influence water solubility of the Mo complex,42 which may in
turn be partly responsible for the enhanced cytotoxicity. DIMEB
may also function as an absorption enhancer, leading to an
increased intracellular accumulation of the drug.43
In conclusion, our data indicate that half-sandwich complexes
of molybdenum are potentially interesting as anticancer agents
and that their bioavailability may be enhanced by combination
with cyclodextrins. These findings call for further investigations
on the mechanism of action and screening of a broader range
of complexes.
Experimental Section
General Comments. All air-sensitive operations were carried
out using standard Schlenk techniques under nitrogen. CH2Cl2 and
MeCN were dried over CaH2, distilled under nitrogen, and kept
over 3 Å (MeCN) or 4 Å (CH2Cl2) molecular sieves. Microanalyses
for CHN were performed at the University of Aveiro, and Mo was
determined by ICP-OES at the Central Laboratory for Analysis
(University of Aveiro) by E. Soares. TGA studies were carried out
using a Shimadzu TGA-50 system at a heating rate of 5 K min-1
under air. Powder XRD data were collected at ambient temperature
on an X’Pert MPD Philips diffractometer (Cu KR X-radiation, λ
) 1.54060 Å) equipped with an X’Celerator detector, curved
graphite-monochromated radiation, and a flat-plate sample holder,
in a Bragg-Brentano para-focusing optics configuration (40 kV,
50 mA). Intensity data were collected in continuous scanning mode
in the ca. 3° e 2θ e 60° angular range. Infrared spectra were
recorded on a Unican Mattson Mod 7000 FTIR spectrophotometer.
13C{1H} CP/MAS NMR spectra were recorded at 125.72 MHz on
a (11.7 T) Bruker Avance 500 spectrometer, with an optimized
π/2 pulse for 1H of 4.5 µs, 2 ms contact time, a spinning rate of 7
kHz, and 12 s recycle delays. Chemical shifts are quoted in parts
per million from tetramethylsilane.
DIMEB was obtained from Fluka and used as received. The
complexes [CpMo(MeCN)2(CO)2](BF4) (1) and [CpMo(H2biim)-
(CO)2](BF4) (2) were prepared according to literature procedures.17,44
1@DIMEB. A solution of DIMEB (0.36 g, 0.27 mmol) in
acetonitrile was added to a solution of 1 (105 mg, 0.27 mmol) in
dry and degassed acetonitrile, and the mixture stirred for 2 h at 40
°C. After cooling to room temperature, the solvent was removed
under reduced pressure to obtain a light red microcrystalline solid.
Anal. Calcd for (C56H98O35) · (C11H11BF4MoN2O2) · 2H2O (1753.4):
C 45.90, H 6.50, N 1.60, Mo 5.47. Found: C 45.96, H 6.56, N
1.10, Mo 5.50. FTIR (KBr, cm-1): 3421s, 2929s, 2837m, 1990w
(νCO), 1904m (νCO), 1643m, 1454m, 1367m, 1332w, 1318sh,
1299w, 1197m, 1159s, 1087vs (νBF), 1050vs, 1024sh, 967s, 949m,
916m, 857m, 765m, 704m, 610s, 585m, 436w, 373w. 13C{1H} CP/
MAS NMR: δ 101.6 (DIMEB, C1), 82.7 (DIMEB, C2,4), 70.5
(DIMEB, C3,5,6), 59.8 (DIMEB, O-Me).
2@DIMEB. A solution of DIMEB (0.15 g, 0.11 mmol) in
dichloromethane was added to a solution of 2 (49 mg, 0.11 mmol)
in dichloromethane and the mixture stirred for 2 h at 40 °C. After
cooling to room temperature, the solvent was removed under
reduced pressure to obtain a light brown microcrystalline solid.
Anal. Calcd for (C56H98O35) · (C13H11BF4MoN4O2) · 3H2O (1823.4):
C 45.45, H 6.36, N 3.07, Mo 5.26. Found: C 45.43, H 6.14, N
3.50, Mo 5.21. FTIR (KBr, cm-1): 3423s, 2927s, 2840m, 2030m,
1976s (νCO), 1890s (νCO), 1731m, 1646m, 1540m, 1461m, 1429m,
1408w, 1371m, 1332w, 1297m, 1260m, 1197m, 1159s, 1087vs
(νBF), 1051vs, 966s, 916m, 863m, 826w, 757m, 736m, 704m, 673w,
609s, 573m, 440m, 376w. 13C{1H} CP/MAS NMR: δ 134.7, 122.5
(H2biim), 102.2 (DIMEB, C1), 96.9 (Cp), 82.9 (DIMEB, C2,4),
71.1 (DIMEB, C3,5,6), 60.4, 60.0, 59.6 (DIMEB, O-Me).
Cell Culture. K1735-M2 mouse melanoma cells (kindly pro-
vided by Dr. Lillian Repesh, Department of Anatomy, Microbiology
and Pathology, University of Minnesota, Medical School, Duluth,
MN) were grown in Dulbecco’s modified Eagle’s medium (DMEM;
Gibco, Grand Island, NY) supplemented with 1.5 g/L sodium
bicarbonate and 10% fetal clone III (FC3; HyClone, Logan, UT)
(40) Balula, S. S.; Coelho, A. C.; Braga, S. S.; Hazell, A.; Valente, A. A.;
Pillinger, M.; Seixas, J. D.; Roma˜o, C. C.; Gonc¸alves, I. S. Organometallics
2007, 26, 6857.
(41) (a) Lichtenthaler, F. W.; Immel, S. Starch/Sta¨rke 1996, 48, 145.
(b) Immel, S.; Lichtenthaler, F. W. Starch/Sta¨rke 1996, 48, 225.
(42) Loftsson, T.; Ma´sson, M.; Brewster, M. E. J. Pharm. Sci. 2004,
93, 1091.
(43) Upadhyay, A. K.; Singh, S.; Chhipa, R. R.; Vijayakumar, M. V.;
Ajay, A. K.; Bhat, M. K. Toxicol. Appl. Pharmacol. 2006, 216, 177.
(44) Drew, M. G. B.; Fe´lix, V.; Gonc¸alves, I. S.; Ku¨hn, F. E.; Lopes,
A. D.; Roma˜o, C. C. Polyhedron 1998, 17, 1091.
Figure 8. Vital imaging of K1735-M2 cells treated with
2@DIMEB. Cells were incubated with TMRM (red mitochondrial
fluorescence, 100 nM), Hoechst 33342 (blue nuclear fluorescence,
1 µg), and calcein-AM (green cytosolic fluorescence, 300 nM) for
30 min at 37 °C. Experiments were performed for 24 and 72 h of
incubation with the compound. Images were obtained with a 40×
phase-contrast objective. For 50 and 100 µM 2@DIMEB, a clear
decrease in the number of cells is visible. Although it appears that
the same happens with 25 µM, the result is due only to the choice
of focal plane. For the two higher concentrations, besides the
decrease in the number of cells, mitochondrial fragmentation
(conversion from long filamentous mitochondria to small round
bodies) is also observed, while cells still maintained viability
(inclusion of calcein fluorescence). For higher time points (72 h),
cells with necrotic phenotype are observed (loss of TMRM and
calcein fluorescence) at the highest concentration.
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in a 5% CO2 atmosphere at 37 °C. Cells were passaged by
trypsinization using standard methods; all experiments were
performed in cells seeded from cultures in log-phase growth. The
H9c2 cell line, originally derived from embryonic rat heart tissue
using selective serial passages,45 was purchased from America
Tissue Type Collection (Manassas, VA; catalog # CRL-1446). Cells
were cultured in DMEM supplemented with 1.5 g/L sodium
bicarbonate, 10% fetal bovine serum, 100 U/mL penicillin, and 100
µg/mL streptomycin in 75 cm2 tissue culture flasks at 37 °C in a
humidified atmosphere of 5% CO2. Cells were fed every 2-3 days
and subcultured once they reached 70-80% confluence.
Cell Proliferation Measurements. Sulforhodamine B assays46
were conducted to measure the effects of the compounds under
study on the proliferation of K1735-M2 cells, essentially as
described by Holy et al.47 H9c2 and K1735-M2 cells were seeded
at a concentration of 1× 104 cells/mL in 48-well plates and allowed
to recover for 1 day prior to drug addition. Vehicle controls were
also performed. After sulforhodamine labeling in acidic buffer,
absorbance was measured in a spectrophotometer at 540 nm; the
amount of dye released is proportional to the number of cells present
in the dish and is a reliable indicator of cell proliferation. Values
were measured in terms of percentage of time zero (i.e., the cell
mass before drug or vehicle treatment) and compared with the
control for the respective time point.
Epifluorescence Imaging of K1735-M2 Cells. Cells were
seeded in glass coverslips at a concentration of 1 × 104 cells/mL.
Cells were allowed to attach for 24 h and then treated with
2@DIMEB or with the vehicle (DMSO) for the desired time. Before
the drug exposure time ended, cells were incubated with TMRM
(100 nM), Hoechst 33342 (1 µg), and calcein-AM (300 nM) diluted
in standard calcium-supplemented Krebs buffer for 30 min at 37
°C in the dark. Before collecting the images, the media with the
fluorescent probes was replaced by fresh Krebs media without probe
addition. Images were collected using a 40× objective in an
epifluorescence Leica DM 4000B.
Statistics. Data are represented as means ( SEM and compared
by using ANOVA followed by the Dunnett’s post-test. A value of
p < 0.05 was considered significant. Analyses were conducted by
using GraphPad Prism 4.0 (GraphPad Software).
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(45) Kimes, B. W.; Brandt, B. L. Exp. Cell Res. 1976, 98, 367.
(46) Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahan, J.;
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